Search

Two Cu(II) metal complexes, {[Cu(bmem)(CH 3 OH)(CH 3 O)](ClO 4)} n (1) and {[Cu(bmem)(CH 3 O)(SCN)](CH 3 OH) 0.75 } n (2) based on 1-(benzotriazole-1-methyl) -1-(2-ethylimidazole) (bmem) were synthesized. The X-ray single crystal diffraction analysis reveals that complexes 1 and 2 both display 1D chain structure containing binuclear copper units. Then the ligand and complexes 1 and 2 were examined for hypoglycemic activity against α-amylase and antioxidant activity against 2,2-diphenyl-1-picrylhydrazyl (DPPH) and found that two Cu(II) complexes showed more activity than the ligand bmem. Both complexes 1 and 2 have strong inhibitory effects on α-amylase, and the IC 50 values of complexes 1 (1.97 mg/mL) and 2 (1.83 mg/mL) are lower than that of acarbose (2.3 mg/mL) and ligand (10.89 mg/mL). The scavenging rates on DPPH radical of complexes 1 (80.46%, 150 μg/mL) and 2 (63.08%, 150 μg/mL) are significantly higher than that of ligand (6.92%, 150 μg/mL). In addition, the fluorescence properties and thermal stability of metal complexes were determined. Image 1 • Two new benzotriazole-based Cu(II) complexes 1 and 2 were synthesized. • Complexes 1 and 2 display 1D chain structure containing binuclear copper units. • The hypoglycemic activities against α-amylase of complexes 1 and 2 were investigated in vitro. • The antioxidant activities of complexes 1 and 2 were evaluated by the DPPH free radical scavenging assay. [ABSTRACT FROM AUTHOR]

Three new complexes formulated as [Cu(mbmb) 2 Cl 2 ] (1), [Cu(mbmb) 2 (NO 3) 2 ] (2), and [Zn(mbmb) 2 Cl 2 ] (3) (mbmb = 1-[(2-methyl-1H-benzoimidazol-1-yl)methyl]-1H-benzotriazole) have been synthesized and characterized. Complexes 1 – 3 showed mononuclear structures and the central metal ions of complexes 1 – 3 exhibited a four-coordinated environment. We evaluated the antioxidant activity against DPPH and antidiabetic activity against α-amylase of complexes 1 – 3 and ligand (mbmb) in vitro. The results of DPPH free radical scavenging assay showed that complexes 1 and 2 exhibited higher antioxidant activity among the synthesized compounds and their IC 50 values were 43.72 μg/mL and 43.76 μg/mL, respectively. The IC 50 values in vitro antidiabetic studies of complex 1 (0.74 mg/mL) and complex 2 (1.00 mg/mL) were much smaller than those of standard acarbose (2.34 mg/mL) and the ligand mbmb (39.87 mg/mL), which showed effective inhibition on α-amylase. Additionally, the solid-state fluorescent properties of these three complexes and ligand mbmb were investigated at room temperature. Unlabelled Image • Three new benzimidazole-based Cu(II)/Zn(II) complexes 1 – 3 were synthesized. • The structure of complexes 1 – 3 was characterized adequately by X-ray study. • The antioxidant activities of complexes 1 – 3 were evaluated by the DPPH free radical scavenging assay. • The antidiabetic activities against α-amylase of complexes 1 – 3 were investigated in vitro. [ABSTRACT FROM AUTHOR]

Three new Zn(II) complexes, namely [Zn(emimb) 2 Cl 2 (1), [Zn(dmimb) 2 Cl 2 (2) and [Zn(bmem) 2 (SCN) 2 (3), have been synthesized using the benzotriazole-based ligands, 1-((2-ethyl-4-methyl-1H-imidazol-1-yl)methyl)-1H-benzotriazole (emimb), 1-((2,4-dimethyl-1H-imidazol-1-yl)methyl)-1H-benzotriazole (dmimb) and 1-((2-ethyl-1H-imidazol-1-yl)methyl)-1H-benzotriazole (bmem). All the complexes were fully characterized by elemental analysis, IR spectroscopy, 1H NMR spectroscopy and single-crystal X-ray diffraction analysis. Complexes 1–3 show mononuclear structures and the central Zn(II) ion of 1 – 3 is four-coordinated in a distorted tetrahedral coordination geometry. Complex 2 presents an interesting 3-D network through two different intermolecular π-π stacking interactions. The antidiabetic activities against α-amylase of ligands and complexes 1–3 are investigated in vitro. The results indicate that the three Zn(II) complexes inhibit α-amylase more strongly than free ligands. Antioxidant tests in vitro show that the complex 3 possesses a mild antioxidant activity against 1,1-diphenyl-picrylhydrazyl (DPPH). In addition, the solid-state photoluminescence properties of ligands and their Zn(II) complexes have been investigated. Image 1 • Three new benzotriazole-based Zn(II) complexes 1–3 were synthesized. • The structure of complexes 1–3 was characterized adequately by X-ray study. • The antidiabetic activities of complexes 1–3 were investigated against α-amylase in vitro. • The antioxidant activities of complexes 1–3 were evaluated by the DPPH free radical scavenging assay. [ABSTRACT FROM AUTHOR]

• A novel Co(II) complex (1) was synthesized and characterized adequately by X-ray study. • The Co(II) complex exhibits a interesting 3-D framework with the Schläfli symbol of (4·82) 2 (84·122)(42·84) 2. • The antidiabetic activity against α-amylase of complex 1 was investigated in vitro. • The antioxidant activity of complex 1 was evaluated by the DPPH free radical scavenging assay. A novel 3D Co(II) complex {[Co 3 (TTTMB) 4 (SCN) 6 ]·3.5H 2 O} n (1) has been synthesized through the reaction of a flexible tripodal ligand 1,3,5-tris(triazol-1-ylmethyl)- 2,4,6-trimethylbenzene (TTTMB) with Co(NO 3) 2 and KSCN. Single crystal X-ray diffraction determination shows that complex 1 crystallizes in the monoclinic space group C2/c and exhibits three crystallographically independent Co(II) ions with the similar coordination environment but different bond lengths and angles. The overall structure of complex 1 can be described as a (3,4)-connected network with the topological notation of (4·82) 2 (84·122)(42·84) 2. The antidiabetic activity against α-amylase and antioxidant activity against 1,1-diphenyl-2-picrylhydrazil (DPPH) of complex 1 are evaluated in vitro. The IC 50 values of the complex 1 on α-amylase and DPPH are 1.27 mg/mL and 1.53 mg/mL, respectively, which are lower than those of corresponding standard acarbose (2.89 mg/mL) and vitamin E (2.39 mg/mL), indicating that the complex 1 is a new potential antidiabetic and antioxidant drug. Additionally, the solid-state fluorescent properties and thermal stability of the complex are investigated at room temperature. [ABSTRACT FROM AUTHOR]

• Two new benzimidazole-based Cd(II) coordination polymers have been designed and synthesized. • The structure of polymers 1–2 was characterized adequately by X-ray study. • The photocatalytic study indicates that both two polymers possess excellent abilities in the degradation of methylene blue (MB) and rhodamine b (RhB). • The degradation efficiencies of polymer 1 for two dyes are both exceed 95%. Two new coordination polymers (CPs) [Cd(mbmb)I 2 ] n (1) and {[Cd 2 (mbmb) 3 I 2 (SCN) 2 ]·0.25(H 2 O)} n (2) have been synthesized with 1-[(2-methyl-1H-benzoimidazol-1-yl)methyl]-1H-benzotriazole (mbmb), and structurally characterized by X-ray single crystal diffraction analysis, elemental analysis, 1H NMR spectra and IR spectra. The X-ray analysis reveals that both polymers 1–2 crystallize in the triclinic space group P-1. Polymer 1 displays 1D chain structure and further connected through two different intermolecular π...π stacking interactions to form a 2D network. Polymer 2 possesses a 2D layer network, which is further extended into more stable 3D architecture. Moreover, polymers 1–2 were examined for photocatalytic degradation activities, and the result shows that they both present outstanding photocatalytic activities for the degradation of MB and RhB with remarkable efficiencies. For MB, the degradation efficiencies are 96.12% (1) and 95.59% (2); for RhB, the degradation efficiencies are 97.14% (1) and 94.51% (2). Polymer 1 shows higher photocatalytic performance in the degradation of MB and RhB. [Display omitted] [ABSTRACT FROM AUTHOR]